Effect of Smoking Cessation on Multiple Sclerosis Prognosis

IMPORTANCE: Smoking tobacco is a well-established risk factor for multiple sclerosis (MS), a chronic inflammatory disorder of the central nervous system usually characterized by bouts and remissions and typically followed by a secondary progressive (SP) course. However, it is not clear whether smoki...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:JAMA neurology 2015-10, Vol.72 (10), p.1-7
Hauptverfasser: Ramanujam, Ryan, Hedström, Anna-Karin, Manouchehrinia, Ali, Alfredsson, Lars, Olsson, Tomas, Bottai, Matteo, Hillert, Jan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 7
container_issue 10
container_start_page 1
container_title JAMA neurology
container_volume 72
creator Ramanujam, Ryan
Hedström, Anna-Karin
Manouchehrinia, Ali
Alfredsson, Lars
Olsson, Tomas
Bottai, Matteo
Hillert, Jan
description IMPORTANCE: Smoking tobacco is a well-established risk factor for multiple sclerosis (MS), a chronic inflammatory disorder of the central nervous system usually characterized by bouts and remissions and typically followed by a secondary progressive (SP) course. However, it is not clear whether smoking after diagnosis is detrimental. OBJECTIVE: To determine whether smoking after MS diagnosis is associated with a change in time to SP disease. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study of patients with prevalent MS who smoked at diagnosis (n = 728) taken from the Genes and Environment in Multiple Sclerosis Study, which consists of patients from the Swedish National MS Registry. The study entrance date was at time of first-year smoking. The study was conducted between November 2008 and December 2011, with patient environmental data collected from November 2009 to March 2011 via questionnaire. Study participants were from all counties in Sweden diagnosed as having MS at the time of the Genes and Environment in Multiple Sclerosis Study and registered in the Swedish National MS Registry. Patients with MS with relapsing-remitting disease course or SP were included. These patients’ conditions were diagnosed according to the McDonald criteria and the patients responded to recruitment letters with detailed questionnaires. EXPOSURE: Smoking, considered yearly after diagnosis and combined into a time-invariant covariate before diagnosis. MAIN OUTCOMES AND MEASURES: Time to SPMS, measured using an accelerated failure time model, with smoking as a time-varying covariate. Other covariates included sex, age at diagnosis, snuff use, and smoking before diagnosis. RESULTS: The optimized model illustrated that each additional year of smoking after diagnosis accelerated the time to conversion to SPMS by 4.7% (acceleration factor, 1.047; 95% CI, 1.023-1.072; P 
doi_str_mv 10.1001/jamaneurol.2015.1788
format Article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_510849</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><ama_id>2432189</ama_id><sourcerecordid>1722185691</sourcerecordid><originalsourceid>FETCH-LOGICAL-a597t-ae3b1da5fb75b6050c7b75a9b4945a115c315a2d2854305c23dbdd9fce2062913</originalsourceid><addsrcrecordid>eNqFkl1LwzAUhoMoKro_ICK99KYzJx9tglcy5wcoClNvQ9qms65tZtMi_nuzdR9XagjkJXnec3KSg9Ap4CFgDBcfutK16RpbDgkGPoRYiB10SCASYQQ83t1oJg_QwLkP7IfAmFG2jw5IRJmICT5El-M8N2kb2DyYVHZW1NNgZJzTbWHrwM_HrmyLeWmCSVqaxrrCBc-NndYLdYz2cl06M1itR-j1Zvwyugsfnm7vR1cPoeYybkNtaAKZ5nkS8yTCHKexV1omTDKuAXhKgWuSEcEZxTwlNEuyTOapITgiEugRCvu47svMu0TNm6LSzbeyulCrrZlXRnHAgknPy1_5eWOzrWltBEpAckzln7mui7crZZupmrXvCgQQSjx_3vM-8GdnXKuqwqWmLP332M4piCkREMllGf-hhIDg0RJlPZr6J3eNyTf3AKwWDaC2DaAWDaAWDeBtZ6sMXVKZbGNaf7cHTnrAu7enzFcvJP0B1Ju3Pw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1722185691</pqid></control><display><type>article</type><title>Effect of Smoking Cessation on Multiple Sclerosis Prognosis</title><source>MEDLINE</source><source>American Medical Association Journals</source><creator>Ramanujam, Ryan ; Hedström, Anna-Karin ; Manouchehrinia, Ali ; Alfredsson, Lars ; Olsson, Tomas ; Bottai, Matteo ; Hillert, Jan</creator><creatorcontrib>Ramanujam, Ryan ; Hedström, Anna-Karin ; Manouchehrinia, Ali ; Alfredsson, Lars ; Olsson, Tomas ; Bottai, Matteo ; Hillert, Jan</creatorcontrib><description>IMPORTANCE: Smoking tobacco is a well-established risk factor for multiple sclerosis (MS), a chronic inflammatory disorder of the central nervous system usually characterized by bouts and remissions and typically followed by a secondary progressive (SP) course. However, it is not clear whether smoking after diagnosis is detrimental. OBJECTIVE: To determine whether smoking after MS diagnosis is associated with a change in time to SP disease. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study of patients with prevalent MS who smoked at diagnosis (n = 728) taken from the Genes and Environment in Multiple Sclerosis Study, which consists of patients from the Swedish National MS Registry. The study entrance date was at time of first-year smoking. The study was conducted between November 2008 and December 2011, with patient environmental data collected from November 2009 to March 2011 via questionnaire. Study participants were from all counties in Sweden diagnosed as having MS at the time of the Genes and Environment in Multiple Sclerosis Study and registered in the Swedish National MS Registry. Patients with MS with relapsing-remitting disease course or SP were included. These patients’ conditions were diagnosed according to the McDonald criteria and the patients responded to recruitment letters with detailed questionnaires. EXPOSURE: Smoking, considered yearly after diagnosis and combined into a time-invariant covariate before diagnosis. MAIN OUTCOMES AND MEASURES: Time to SPMS, measured using an accelerated failure time model, with smoking as a time-varying covariate. Other covariates included sex, age at diagnosis, snuff use, and smoking before diagnosis. RESULTS: The optimized model illustrated that each additional year of smoking after diagnosis accelerated the time to conversion to SPMS by 4.7% (acceleration factor, 1.047; 95% CI, 1.023-1.072; P &lt; .001). Kaplan-Meier plots demonstrated that those who continued to smoke continuously each year after diagnosis converted to SPMS faster than those who quit smoking, reaching SP disease at 48 and 56 years of age, respectively. CONCLUSIONS AND RELEVANCE: This study provides evidence that continued smoking is associated with an acceleration in time to SPMS and that those who quit fare better. Therefore, we propose that patients with MS should be advised to stop smoking once a diagnosis has been made, not only to lessen risks for comorbidities, but also to avoid aggravating MS-related disability.</description><identifier>ISSN: 2168-6149</identifier><identifier>ISSN: 2168-6157</identifier><identifier>EISSN: 2168-6157</identifier><identifier>DOI: 10.1001/jamaneurol.2015.1788</identifier><identifier>PMID: 26348720</identifier><language>eng</language><publisher>United States: American Medical Association</publisher><subject>Adult ; age ; controlled study ; Cross-Sectional Studies ; cross-sectional study ; Disease Progression ; Female ; human ; Humans ; Kaplan Meier method ; major clinical study ; Male ; Medicin och hälsovetenskap ; Middle Aged ; multiple sclerosis ; Multiple Sclerosis - diagnosis ; Multiple Sclerosis - physiopathology ; prevalence ; priority journal ; Prognosis ; questionnaire ; register ; Risk Factors ; sex ; smokeless tobacco ; smoking ; Smoking - adverse effects ; Smoking Cessation ; Sweden</subject><ispartof>JAMA neurology, 2015-10, Vol.72 (10), p.1-7</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a597t-ae3b1da5fb75b6050c7b75a9b4945a115c315a2d2854305c23dbdd9fce2062913</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://jamanetwork.com/journals/jamaneurology/articlepdf/10.1001/jamaneurol.2015.1788$$EPDF$$P50$$Gama$$H</linktopdf><linktohtml>$$Uhttps://jamanetwork.com/journals/jamaneurology/fullarticle/10.1001/jamaneurol.2015.1788$$EHTML$$P50$$Gama$$H</linktohtml><link.rule.ids>64,230,315,782,786,887,3344,27933,27934,76499,76502</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26348720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-181232$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:132195039$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Ramanujam, Ryan</creatorcontrib><creatorcontrib>Hedström, Anna-Karin</creatorcontrib><creatorcontrib>Manouchehrinia, Ali</creatorcontrib><creatorcontrib>Alfredsson, Lars</creatorcontrib><creatorcontrib>Olsson, Tomas</creatorcontrib><creatorcontrib>Bottai, Matteo</creatorcontrib><creatorcontrib>Hillert, Jan</creatorcontrib><title>Effect of Smoking Cessation on Multiple Sclerosis Prognosis</title><title>JAMA neurology</title><addtitle>JAMA Neurol</addtitle><description>IMPORTANCE: Smoking tobacco is a well-established risk factor for multiple sclerosis (MS), a chronic inflammatory disorder of the central nervous system usually characterized by bouts and remissions and typically followed by a secondary progressive (SP) course. However, it is not clear whether smoking after diagnosis is detrimental. OBJECTIVE: To determine whether smoking after MS diagnosis is associated with a change in time to SP disease. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study of patients with prevalent MS who smoked at diagnosis (n = 728) taken from the Genes and Environment in Multiple Sclerosis Study, which consists of patients from the Swedish National MS Registry. The study entrance date was at time of first-year smoking. The study was conducted between November 2008 and December 2011, with patient environmental data collected from November 2009 to March 2011 via questionnaire. Study participants were from all counties in Sweden diagnosed as having MS at the time of the Genes and Environment in Multiple Sclerosis Study and registered in the Swedish National MS Registry. Patients with MS with relapsing-remitting disease course or SP were included. These patients’ conditions were diagnosed according to the McDonald criteria and the patients responded to recruitment letters with detailed questionnaires. EXPOSURE: Smoking, considered yearly after diagnosis and combined into a time-invariant covariate before diagnosis. MAIN OUTCOMES AND MEASURES: Time to SPMS, measured using an accelerated failure time model, with smoking as a time-varying covariate. Other covariates included sex, age at diagnosis, snuff use, and smoking before diagnosis. RESULTS: The optimized model illustrated that each additional year of smoking after diagnosis accelerated the time to conversion to SPMS by 4.7% (acceleration factor, 1.047; 95% CI, 1.023-1.072; P &lt; .001). Kaplan-Meier plots demonstrated that those who continued to smoke continuously each year after diagnosis converted to SPMS faster than those who quit smoking, reaching SP disease at 48 and 56 years of age, respectively. CONCLUSIONS AND RELEVANCE: This study provides evidence that continued smoking is associated with an acceleration in time to SPMS and that those who quit fare better. Therefore, we propose that patients with MS should be advised to stop smoking once a diagnosis has been made, not only to lessen risks for comorbidities, but also to avoid aggravating MS-related disability.</description><subject>Adult</subject><subject>age</subject><subject>controlled study</subject><subject>Cross-Sectional Studies</subject><subject>cross-sectional study</subject><subject>Disease Progression</subject><subject>Female</subject><subject>human</subject><subject>Humans</subject><subject>Kaplan Meier method</subject><subject>major clinical study</subject><subject>Male</subject><subject>Medicin och hälsovetenskap</subject><subject>Middle Aged</subject><subject>multiple sclerosis</subject><subject>Multiple Sclerosis - diagnosis</subject><subject>Multiple Sclerosis - physiopathology</subject><subject>prevalence</subject><subject>priority journal</subject><subject>Prognosis</subject><subject>questionnaire</subject><subject>register</subject><subject>Risk Factors</subject><subject>sex</subject><subject>smokeless tobacco</subject><subject>smoking</subject><subject>Smoking - adverse effects</subject><subject>Smoking Cessation</subject><subject>Sweden</subject><issn>2168-6149</issn><issn>2168-6157</issn><issn>2168-6157</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkl1LwzAUhoMoKro_ICK99KYzJx9tglcy5wcoClNvQ9qms65tZtMi_nuzdR9XagjkJXnec3KSg9Ap4CFgDBcfutK16RpbDgkGPoRYiB10SCASYQQ83t1oJg_QwLkP7IfAmFG2jw5IRJmICT5El-M8N2kb2DyYVHZW1NNgZJzTbWHrwM_HrmyLeWmCSVqaxrrCBc-NndYLdYz2cl06M1itR-j1Zvwyugsfnm7vR1cPoeYybkNtaAKZ5nkS8yTCHKexV1omTDKuAXhKgWuSEcEZxTwlNEuyTOapITgiEugRCvu47svMu0TNm6LSzbeyulCrrZlXRnHAgknPy1_5eWOzrWltBEpAckzln7mui7crZZupmrXvCgQQSjx_3vM-8GdnXKuqwqWmLP332M4piCkREMllGf-hhIDg0RJlPZr6J3eNyTf3AKwWDaC2DaAWDaAWDeBtZ6sMXVKZbGNaf7cHTnrAu7enzFcvJP0B1Ju3Pw</recordid><startdate>20151001</startdate><enddate>20151001</enddate><creator>Ramanujam, Ryan</creator><creator>Hedström, Anna-Karin</creator><creator>Manouchehrinia, Ali</creator><creator>Alfredsson, Lars</creator><creator>Olsson, Tomas</creator><creator>Bottai, Matteo</creator><creator>Hillert, Jan</creator><general>American Medical Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7TK</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8V</scope></search><sort><creationdate>20151001</creationdate><title>Effect of Smoking Cessation on Multiple Sclerosis Prognosis</title><author>Ramanujam, Ryan ; Hedström, Anna-Karin ; Manouchehrinia, Ali ; Alfredsson, Lars ; Olsson, Tomas ; Bottai, Matteo ; Hillert, Jan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a597t-ae3b1da5fb75b6050c7b75a9b4945a115c315a2d2854305c23dbdd9fce2062913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>age</topic><topic>controlled study</topic><topic>Cross-Sectional Studies</topic><topic>cross-sectional study</topic><topic>Disease Progression</topic><topic>Female</topic><topic>human</topic><topic>Humans</topic><topic>Kaplan Meier method</topic><topic>major clinical study</topic><topic>Male</topic><topic>Medicin och hälsovetenskap</topic><topic>Middle Aged</topic><topic>multiple sclerosis</topic><topic>Multiple Sclerosis - diagnosis</topic><topic>Multiple Sclerosis - physiopathology</topic><topic>prevalence</topic><topic>priority journal</topic><topic>Prognosis</topic><topic>questionnaire</topic><topic>register</topic><topic>Risk Factors</topic><topic>sex</topic><topic>smokeless tobacco</topic><topic>smoking</topic><topic>Smoking - adverse effects</topic><topic>Smoking Cessation</topic><topic>Sweden</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ramanujam, Ryan</creatorcontrib><creatorcontrib>Hedström, Anna-Karin</creatorcontrib><creatorcontrib>Manouchehrinia, Ali</creatorcontrib><creatorcontrib>Alfredsson, Lars</creatorcontrib><creatorcontrib>Olsson, Tomas</creatorcontrib><creatorcontrib>Bottai, Matteo</creatorcontrib><creatorcontrib>Hillert, Jan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Neurosciences Abstracts</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Kungliga Tekniska Högskolan</collection><jtitle>JAMA neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ramanujam, Ryan</au><au>Hedström, Anna-Karin</au><au>Manouchehrinia, Ali</au><au>Alfredsson, Lars</au><au>Olsson, Tomas</au><au>Bottai, Matteo</au><au>Hillert, Jan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Smoking Cessation on Multiple Sclerosis Prognosis</atitle><jtitle>JAMA neurology</jtitle><addtitle>JAMA Neurol</addtitle><date>2015-10-01</date><risdate>2015</risdate><volume>72</volume><issue>10</issue><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>2168-6149</issn><issn>2168-6157</issn><eissn>2168-6157</eissn><abstract>IMPORTANCE: Smoking tobacco is a well-established risk factor for multiple sclerosis (MS), a chronic inflammatory disorder of the central nervous system usually characterized by bouts and remissions and typically followed by a secondary progressive (SP) course. However, it is not clear whether smoking after diagnosis is detrimental. OBJECTIVE: To determine whether smoking after MS diagnosis is associated with a change in time to SP disease. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional study of patients with prevalent MS who smoked at diagnosis (n = 728) taken from the Genes and Environment in Multiple Sclerosis Study, which consists of patients from the Swedish National MS Registry. The study entrance date was at time of first-year smoking. The study was conducted between November 2008 and December 2011, with patient environmental data collected from November 2009 to March 2011 via questionnaire. Study participants were from all counties in Sweden diagnosed as having MS at the time of the Genes and Environment in Multiple Sclerosis Study and registered in the Swedish National MS Registry. Patients with MS with relapsing-remitting disease course or SP were included. These patients’ conditions were diagnosed according to the McDonald criteria and the patients responded to recruitment letters with detailed questionnaires. EXPOSURE: Smoking, considered yearly after diagnosis and combined into a time-invariant covariate before diagnosis. MAIN OUTCOMES AND MEASURES: Time to SPMS, measured using an accelerated failure time model, with smoking as a time-varying covariate. Other covariates included sex, age at diagnosis, snuff use, and smoking before diagnosis. RESULTS: The optimized model illustrated that each additional year of smoking after diagnosis accelerated the time to conversion to SPMS by 4.7% (acceleration factor, 1.047; 95% CI, 1.023-1.072; P &lt; .001). Kaplan-Meier plots demonstrated that those who continued to smoke continuously each year after diagnosis converted to SPMS faster than those who quit smoking, reaching SP disease at 48 and 56 years of age, respectively. CONCLUSIONS AND RELEVANCE: This study provides evidence that continued smoking is associated with an acceleration in time to SPMS and that those who quit fare better. Therefore, we propose that patients with MS should be advised to stop smoking once a diagnosis has been made, not only to lessen risks for comorbidities, but also to avoid aggravating MS-related disability.</abstract><cop>United States</cop><pub>American Medical Association</pub><pmid>26348720</pmid><doi>10.1001/jamaneurol.2015.1788</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-6149
ispartof JAMA neurology, 2015-10, Vol.72 (10), p.1-7
issn 2168-6149
2168-6157
2168-6157
language eng
recordid cdi_swepub_primary_oai_swepub_ki_se_510849
source MEDLINE; American Medical Association Journals
subjects Adult
age
controlled study
Cross-Sectional Studies
cross-sectional study
Disease Progression
Female
human
Humans
Kaplan Meier method
major clinical study
Male
Medicin och hälsovetenskap
Middle Aged
multiple sclerosis
Multiple Sclerosis - diagnosis
Multiple Sclerosis - physiopathology
prevalence
priority journal
Prognosis
questionnaire
register
Risk Factors
sex
smokeless tobacco
smoking
Smoking - adverse effects
Smoking Cessation
Sweden
title Effect of Smoking Cessation on Multiple Sclerosis Prognosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T16%3A36%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Smoking%20Cessation%20on%20Multiple%20Sclerosis%20Prognosis&rft.jtitle=JAMA%20neurology&rft.au=Ramanujam,%20Ryan&rft.date=2015-10-01&rft.volume=72&rft.issue=10&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=2168-6149&rft.eissn=2168-6157&rft_id=info:doi/10.1001/jamaneurol.2015.1788&rft_dat=%3Cproquest_swepu%3E1722185691%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1722185691&rft_id=info:pmid/26348720&rft_ama_id=2432189&rfr_iscdi=true